Cancer
The oncolytic virus cancer therapy pipeline landscape is booming, with over 120 active players working to develop more than 125 pipeline therapies for the treatment of cancer. The pipeline is filled with promising oncolytic virus therapies, many of which are in the advanced stages of clinical development. These therapies aim
Cancer
Researchers from Huazhong University of Science and Technology have made a groundbreaking discovery in the field of gastric cancer, identifying a novel biomarker that can predict prognosis and evaluate the tumor immune microenvironment. The team, led by Liduan Zheng, used data from The Cancer Genome Atlas and Gene Expression Omnibus
Cancer
A recent study published in Reactive & Functional Polymers has demonstrated the efficacy of polyethyleneimine cross-linked non-reducing oligosaccharides in gene delivery to cancer cells. The research, conducted by researchers at the Harbin Institute of Technology, has shown that oligosaccharide modification represents a promising strategy for developing PEI-based gene delivery systems
Cancer
Recent research from Tianjin University in Tianjin, People's Republic of China, has shed light on the potential of gene therapy in cancer treatment. According to the study, gene therapy has distinct advantages over conventional therapies, including reduced dosing requirements, lower toxicity, and a lower risk of drug resistance.
Cancer
For many people with cancer in the UK, access to timely and effective care is not a guarantee, regardless of the quality of treatment available. A recent analysis conducted by Macmillan Cancer Support reveals that an estimated 40% of cancer patients have faced barriers to care due to their geographical
Cancer
Researchers at the Mayo Clinic have recently published a study on the use of patient-reported outcomes (PROs) in cancer clinical trials. The US Food and Drug Administration (FDA) has released a draft guidance document that outlines the core PROs that should be included in cancer clinical trials, including physical function
Cancer
Researchers from the School of Chemical and Pharmaceutical Engineering have made a significant discovery in the treatment of metastatic cancer. A new study published in the Chemical Engineering Journal has demonstrated the effectiveness of ultrasmall dendrimer nanodots in targeted chemotherapy and enhanced photodynamic/immunotherapy of metastatic cancer. The research has
Cancer
Research conducted by Chaofan Chen and colleagues at Kunming Municipal Hospital of Traditional Chinese Medicine in Yunnan, People's Republic of China, has shed light on the potential of nanoparticle-based immunotherapy in treating gastric cancer. The study highlights the limitations of current therapeutic strategies and introduces nanomedicine as a
Cancer
Investigators at Shanghai Jiao Tong University have made significant progress in understanding the molecular subtypes of gastric cancer, which has crucial implications for the development of novel therapeutic strategies. According to a recent study, gastric cancers are classified into four molecular subtypes, including Epstein-Barr virus-positive (EBV-positive), microsatellite instability-high (MSI-H), chromosomal
Cancer
Immunotherapy has transformed cancer treatment by leveraging the body's natural defenses to target and destroy cancer cells. However, evaluating its effectiveness presents unique challenges. Advanced imaging techniques play a crucial role in guiding decisions and improving patient outcomes in immunotherapy clinical trials. These techniques, including immunoPET, offer a
Cancer
At the Royal Preston Hospital, a new way of serving fruit to patients is underway. Instead of individual fruit slices and canapés, patients will now receive a fruit pot containing a mixture of chopped fruits, freshly squeezed fruit juices, and sweet treats like mini chocolate éclairs, macarons, and cake bites.
Cancer
Research conducted at the University of Texas MD Anderson Cancer Center has shown promising results for the treatment of follicular lymphoma using acalabrutinib, lenalidomide, and rituximab. The phase II trial involved 24 patients with previously untreated follicular lymphoma and high tumor burden, who were treated with the combination of drugs.
